Prucalopride

Generic Name
Prucalopride
Brand Names
Motegrity, Resolor, Resotran
Drug Type
Small Molecule
Chemical Formula
C18H26ClN3O3
CAS Number
179474-81-8
Unique Ingredient Identifier
0A09IUW5TP
Background

Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride...

Indication

Prucalopride is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

CIC is one of the most common chronic functional gastrointestinal disorders worldwide. The diagnosis of this agent is very hard and it can be confirmed if the patient experience at least two of the following:
...

Associated Conditions
Opioid Induced Constipation (OIC), Chronic idiopathic constipation (CIC), Refractory Chronic idiopathic constipation
Associated Therapies
-
Clinical Trials
Related News

Improving Bowel Preparation for the Colon Capsule

First Posted Date
2012-08-01
Last Posted Date
2015-12-03
Lead Sponsor
Queen's University
Target Recruit Count
20
Registration Number
NCT01655095
Locations
🇨🇦

Hotel Dieu Hospital, Kingston, Ontario, Canada

Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years

Phase 4
Completed
Conditions
Constipation
Interventions
Drug: placebo
Drug: prucalopride
First Posted Date
2011-08-26
Last Posted Date
2021-06-11
Lead Sponsor
Shire
Target Recruit Count
364
Registration Number
NCT01424228
Locations
🇭🇺

Békés Megyei Képviselotestület Pándy Kálmán Kórháza, Gyula, Bekes, Hungary

🇵🇱

Krakowskie Centrum Medyczne NZOZ, Krakow, Malopolskie, Poland

🇵🇱

Endoskopia Sp. z o.o., Sopot, Pomorskie, Poland

and more 57 locations

Prucalopride in Pediatric Subjects With Functional Constipation

First Posted Date
2011-04-06
Last Posted Date
2021-06-10
Lead Sponsor
Shire
Target Recruit Count
215
Registration Number
NCT01330381
Locations
🇳🇱

Academisch Medisch Centrum, Amsterdam, Netherlands

Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic Constipation

First Posted Date
2010-12-02
Last Posted Date
2012-08-31
Lead Sponsor
Norgine
Target Recruit Count
240
Registration Number
NCT01251822
Locations
🇷🇴

Pierrel Research, Timisoara, Romania

Evaluation of Prucalopride in Male Subjects With Chronic Constipation.

First Posted Date
2010-06-22
Last Posted Date
2021-06-10
Lead Sponsor
Shire
Target Recruit Count
374
Registration Number
NCT01147926
Locations
🇧🇪

Cliniques Universitaires St Luc, Bruxelles, Belgium

🇧🇪

CHU Sart Tilman, Liege, Belgium

🇳🇱

Meander Medisch Centrum, Amersfoort, Netherlands

and more 68 locations

Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
Drug: prucalopride
First Posted Date
2010-05-31
Last Posted Date
2012-04-19
Lead Sponsor
Movetis
Target Recruit Count
24
Registration Number
NCT01134185

Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation

First Posted Date
2010-05-05
Last Posted Date
2021-06-11
Lead Sponsor
Shire
Target Recruit Count
174
Registration Number
NCT01117051

An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation

Phase 3
Completed
Conditions
Constipation
Interventions
Drug: Prucalopride
Drug: Placebo
First Posted Date
2010-05-04
Last Posted Date
2017-03-21
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
507
Registration Number
NCT01116206

Study to Evaluate Long-Term Tolerability and Safety of Oral Prucalopride in Chronic Constipation

Phase 3
Completed
Conditions
Chronic Constipation
First Posted Date
2010-02-18
Last Posted Date
2010-03-02
Lead Sponsor
Movetis
Target Recruit Count
693
Registration Number
NCT01070615
Locations
🇧🇪

University Hospital Antwerp, Edegem, Belgium

M0001 Effects on Oral Contraceptive Plasma Levels

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: prucalopride
First Posted Date
2009-12-21
Last Posted Date
2011-05-17
Lead Sponsor
Movetis
Target Recruit Count
16
Registration Number
NCT01036893
Locations
🇩🇪

FOCUS GmbH, Neuss, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy